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Abstract O-GlcNAcylation is an abundant, dynamic,
and inducible posttranslational modiﬁcation in which
single b-N-acetylglucosamine residues are attached by O-
glycosidic linkage to serine or treonine residues. It is
suggested that abnormally regulated O-GlcNAcylation
may contribute to the pathology of cancer. Cycling of O-
GlcNAc residues on intracellular proteins is controlled
by two enzymes, O-GlcNAc transferease (OGT), which
catalyses the addition of O-GlcNAc residues and nucle-
ocytoplasmic b-N-acetylglucosaminidase (O-GlcNAcase;
encoded by MGEA5 gene), an enzyme involved in the
removal of O-GlcNAc. In this study, relationship
between the mRNA expressions of genes coding
O-GlcNAc cycling enzymes in breast ductal carcinomas
and clinicopathological parameters were analyzed. The
results showed that poorly differentiated tumors (grade II
and III) had signiﬁcantly higher OGT expression than
grade I tumors. Contrary, MGEA5 transcript levels were
signiﬁcantly lower in grade II and III in comparison with
grade I tumors. The Spearman rank correlation showed
the expressions of OGT and MGEA5 in breast cancer
was negatively correlated (r =- 0.430, P = 0.0002).
Lymph node metastasis status was signiﬁcantly associ-
ated with decreased MGEA5 mRNA expression. This
result suggests that elevation in O-GlcNAc modiﬁcation
of proteins may be implicated in breast tumor progres-
sion and metastasis.
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Introduction
Multiple nucleocytoplasmic proteins, including transcrip-
tion factors, cytoskeletal proteins, oncogenes, and kinases,
are modiﬁed with b-N-acetylglucosamine residues
attached by O-b-glycosidic linkage (O-GlcNAc) [1–3]. O-
GlcNAc is a dynamic and inducible posttranslational
modiﬁcation involved in protein regulation in a manner
similar to phosphorylation. O-GlcNAc level on many
proteins rapidly changes in response to different physio-
logical stimuli, such as hormones, growth factors, and
mitogens [4]. There is a relationship between O-GlcNA-
cylation and phosphorylation. All O-GlcNAc modiﬁed
proteins are also phosphoproteins, and sometimes O-
GlcNAc and O-phosphate moieties can compete for a
binding site or alternatively O-GlcNAcylation and phos-
phorylation can compete via steric hindrance when the
substrate modiﬁcation sites are within 10 aminoacids from
each other [5]. O-GlcNAc can modulate protein function
by regulating protein activity, protein–protein interaction,
localization, and protein degradation [6].
Unlike phosphorylation, which is determined by hun-
dreds of kinases and phosphatases, cycling of O-GlcNAc
residues on intracellular proteins is controlled only by two
highly conserved enzymes. O-GlcNAc transferase (OGT)
catalyses the addition of O-GlcNAc to proteins, and nu-
cleocytoplasmic b-N-acetylglucosaminidase (O-GlcNA-
case) is an enzyme involved in the removal of O-GlcNAc.
The cloned sequence of O-GlcNAcase was found to be
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gen 5), which had been identiﬁed genetically in human
meningiomas [7, 8].
Abnormally regulated O-GlcNAc has been found to be
implicated in diabetes and neurodegenerative diseases [9].
It is also strongly suggested that alterations in O-GlcNAc
cycling may contribute to the pathology of other human
diseases, including cancers [10, 11]. Overexpression of
OGT causes defective cytokinesis increasing polyploidy of
cells, a feature common to many cancer cells [12]. O-
GlcNAc is present in many transcription and cell cycle
regulatory proteins. The protooncogene c-Myc, which
regulates transcription of genes involved in cell prolifera-
tion, apoptosis, and metabolism is modiﬁed by O-GlcNAc
at Thr58. This treonine residue within transactivation
domain is also a GSK3b phosphorylation site. Phosphor-
ylation of this site reduces protein stability and leads to
c-Myc degradation and a reduction in c-Myc target gene
expression. By contrast, an O-GlcNAc residue at Thr58 can
block phosphorylation and potentially stabilize the protein.
Frequent mutation of this site is found in human lympho-
mas, demonstrating the importance of this site in tumor
progression [13]. The important tumor suppressor p53,
which is mutant or dysregulated in nearly all cancers bears
O-GlcNAc at Ser149. The stability of p53 is also tightly
reduced by phosphorylation. O-GlcNAcylation of Ser149
reduces phosphorylation at Thr155, which subsequently
blocks the interaction with Mdm2, an E3 ubiquitin ligase.
Thus, increased O-GlcNAcylation of p53 at Ser149 results
in decreased p53 ubiquitination and stabilizes the p53
protein [14].
O-GlcNAc and phosphorylation crosstalk can be more
complicated than only competition between the two mod-
iﬁcations on the same proteins. Cell has to keep a right
balance between these two modiﬁcations to survive and
develop normally. Alterations in O-GlcNAcylation play a
role in tumorigenesis and progression of cancers. It has
been shown that breast cancer cell lines contain elevated O-
GlcNAcylation and OGT mRNA levels compared with
normal cell lines [15]. Yu and coworkers have demon-
strated that O-GlcNAcylation level of lung, colon, and
breast cancer tissue is signiﬁcantly increased compared
with that in corresponding adjacent tissues [16, 17]. The
intracellular O-GlcNAcylation has been found to be asso-
ciated also with the pathogenesis of chronic lymphatic
leukemia (CLL) [18]. However, aggressive clinical
behavior of CLL cells was found to correlate with lower O-
GlcNAc level.
In this study, we analyzed OGT and MGEA5 mRNAs
expression levels in breast ductal carcinomas and the
relationship between their expression and clinicopatho-
logical parameters such as tumor grade, lymph node
metastasis status or estrogen, and progesterone status.
Materials and methods
Patients and samples
The studied material was obtained from Department of
Clinical Pathomorphology Polish Mother’s Memorial
Hospital, Research Institute, Ło ´dz ´, Poland and comprised
samples of 70 breast ductal carcinomas. The mean patient
age was 57 (range 39–72). Tumor grade was assessed
according to Bloom-Richardson criteria (21 tumors were of
grade I, 30 of grade II and 19 of grade III). Twenty-six
tumor samples were classiﬁed as lymph node metastasis
positive and 44 as lymph node negative. Both estrogen
receptor (ER) and progesterone receptor (PR) expression
was stated in 33 tumor samples. Twenty-one samples were
negative for both receptors and 16 showed expression one
of the two receptors. Tissue samples of 24 normal breasts
were obtained from women undergoing radical
mastectomy.
Total RNA extraction and cDNA synthesis
Total RNA was extracted using TRI Reagent (Sigma–
Aldrich, USA) according to manufacturer’s protocol. RNA
was eluted in 20 ll RNase-free water, quantiﬁed by spec-
trophotometry at 260 nm and stored at -20C. RNA with a
260/280 nm ratio in range 1.8–2.0 was considered high
quality. First strand cDNAs were obtained by reverse
transcription of 1 lg of total RNA using RevertAid
TM First
strand cDNA synthesis kit (Fermentas International, Lith-
uania) following the manufacturer’s protocol.
Real-time quantitative PCR
Real-time ampliﬁcation of the cDNA was performed using
TaqMan
 Gene Expression Assay (Applied Biosystems)
according to manufacturer’s instruction. The ﬂuorogenic,
FAM labeled probes, and the sequence-speciﬁc primers for
OGT, MGEA5, and internal control GAPDH were obtained
as inventoried assays (Hs00201970, Hs00269228 and
Hs99999905, respectively). In samples with positive
expression of target genes, the curve of ﬂuorescence
quantitative ampliﬁcation showed an typical S-line, and in
negative samples, the curve was an irregular wavy line. All
positive samples had Ct (cycle threshold) B30. If the Ct
mean value was more than 40, the sample was deﬁned as
negative in the expression of the target gene. The level of
OGT and MGEA5 mRNA in samples with positive
expression was quantiﬁed by the DCt method. DCt
(Ctgene—CtGAPDH) values were recalculated into rela-
tive copy number values (number of OGT or MGEA5
mRNA copies per 1,000 copies of GAPDH mRNA).
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The statistical analyses were performed using the STAT-
ISTICA version 9.0 (StatSoft, Poland). Since levels of
expression in breast cancer specimens did not show normal
distribution (Kolmogorov–Smirnov test), the nonparamet-
rical statistical tests (Mann–Whitney U test, Kruskal–
Wallis test or the Spearaman rank correlation test) were
applied.
The chi-square test was used to identify relationship
between expression of OGT or MGEA5 and clinicopatho-
logical parameters. A P value \0.05 was considered as
statistically signiﬁcant.
Results and discussion
There are not many data available concerning the expres-
sion and activity of O-GlcNAc cycling enzymes in human
cancers. Mi et al. [16] analyzed by immunohistochemistry
the expressions of OGT and O-GlcNAcase in lung and
colon cancers. They found that OGT expression was ele-
vated in both lung and colon tumor tissues compared with
their corresponding adjacent tissues. Elevated OGT mRNA
expression had been found in breast cancer cell lines and
breast invasive ductal carcinoma compared with normal
breast cells and normal breast tissue [15]. One study
evaluated the usefulness of MGEA5 expression status of
breast cancer cells in revealing tumorigenesis. Dahl et al.
[19] deﬁned a set of candidate genes that are predominantly
localized in the most frequently altered chromosomal
regions known to be important in the pathogenesis of breast
and ovarian cancers and then performed systematic char-
acterization of these candidate genes by cDNA dot blot
using cancer proﬁling array and real-time reverse tran-
scription –PCR (RT–PCR) analysis. MGEA5 was one of
the analyzed genes. Authors compared mRNA expression
of MGEA5 in matched tumor/normal samples of 24 inva-
sive ductal breast cancers. The results showed down-reg-
ulated expression of MGEA5 in tumor samples. Slawson
et al. [20] investigated O-GlcNAcase activity using bio-
chemical assay in 12 primary breast tumors compared with
matched adjacent breast tissue. They demonstrated an
increase in O-GlcNAcase activity in breast tumor tissue
compared with normal tissue. However, because the data
set was relatively small, there was no clear correlation with
tumor grade or type. The results showing increased activity
of O-GlcNAcase in breast cancer are not consistent with
MGEA5 mRNA expression results.
The aim of our study was to establish whether there is
any correlation between OGT and MGEA5 expression and
tumor grade, lymph node metastasis status or ER/PR status
of human breast cancer. Levels of OGT and MGEA5
mRNAs were determined in tumor samples from 70
patients with breast ductal carcinomas and in 24 samples of
normal breast tissue. In normal breast tissue, OGT was
expressed only in 66.7% of samples (16/24) and MGEA5 in
100% of samples (24/24). Positive expression of OGT was
found in 59 and MGEA5 in 57 of 70 carcinoma cases. The
OGT expression was most frequently observed in grade III
tumors (94%), while MGEA5 was most frequently
expressed in grade I tumors (95.2%) (Table 1). There was
no statistically signiﬁcant differences in MGEA5 expres-
sion frequency between grade I and grade II groups.
However, the results showed a trend of poorly differenti-
ated tumors (grade II and III) to be less frequently MGEA5
positive than well differentiated ones (grade I). The dif-
ference between grade I and III was statistically signiﬁcant
(P = 0.02). The expression level of OGT mRNA was
signiﬁcantly lower in normal tissue compared with carci-
noma tissue (Fig. 1). The expression of OGT mRNA was
signiﬁcantly higher in grade II and III tumors than in grade
I tumors (P\0.05, Fig. 1). Contrary, MGEA5 transcript
levels were signiﬁcantly lower in grade II and III in com-
parison with grade I tumors. The results of Spearman rank
correlation showed the expressions of OGT and MGEA5 in
breast cancers were negatively correlated (r =- 0.430,
P = 0.0002). Lymph node metastasis status was signiﬁ-
cantly associated with decreased MGEA5 mRNA expres-
sion (P\0.05) but not with OGT mRNA expression. Both
OGT and MGEA5 expression proﬁles showed no signiﬁ-
cant differences in association with different estrogen and
progesterone status (Fig. 1).
Our results showing decrease in MGEA5 and increase in
OGT expression in higher grade tumors are in agreement
with earlier ﬁndings suggesting that increased O-GlcNAc
modiﬁcation may be implicated in breast tumor
Table 1 Expression of OGT and MGEA5 in ductal breast carcinoma
and normal breast tissue
Clinical characteristics OGT positive/total % MGEA5
positive/total %
Normal tissue 16/24 (66.7) 24/24 (100)
Tumor grade
I 17/21 (80.9) 20/21 (95.2)
II 24/30 (80.0) 24/30 (80.0)
III 18/19 (94.7) 13/19 (68.4)
Lymph node metastasis
No 37/44 (84.1) 39/44 (88.6)
Yes 22/26 (84.6) 18/26 (69.2)
ER and PR status
ER? PR? 28/33 (84.8) 26/33 (78.8)
ER? PR-/ER-PR? 13/16 (81.3) 15/16 (93.7)
ER- PR- 18/21 (85.7) 16/21 (76.2)
Clin Exp Med (2012) 12:61–65 63
123progression and metastasis. Gu et al. [17] demonstrated
that high O-GlcNAcylation enhanced the migration of
breast cancer cells in vitro and lung metastasis in vivo.
Moreover, Caldwell et al. [15] showed that reduction in O-
GlcNAc level through RNA interference of OGT trans-
ferase in breast cancer cells lead to inhibition of tumor
growth and is associated with decreased cancer cell inva-
sion. Thus, the increase in O-GlcNAcylation seems to be
beneﬁcial to breast cancer cells. Negative correlation in
expression of both enzymes may suggest that observed
earlier abnormally high level of O-GlcNAcylation in breast
cancer cells is not only an effect of increased level in
O-GlcNAc transferase but also depends on decreased level
in O-GlcNAcase. We suggest that diagnosis, evaluation of
metastasis potential and prognosis, would beneﬁt from the
combined detection of OGT and MGEA5 expression.
The ﬁndings in this study suggest that O-GlcNAc
cycling enzymes may be related to invasion and metastasis
of ductal breast carcinoma and may become an important
indicator for tumor progression. Further studies on O-
GlcNAc cycling enzymes in breast cancer cells can provide
insights into the molecular mechanism of disease pro-
gression and potentially new therapeutic targets.
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